RPRX vs. BMY
Compare and contrast key facts about Royalty Pharma plc (RPRX) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RPRX or BMY.
Correlation
The correlation between RPRX and BMY is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
RPRX vs. BMY - Performance Comparison
Key characteristics
RPRX:
0.55
BMY:
1.00
RPRX:
1.14
BMY:
1.70
RPRX:
1.13
BMY:
1.21
RPRX:
0.28
BMY:
0.60
RPRX:
1.25
BMY:
2.51
RPRX:
11.01%
BMY:
11.49%
RPRX:
24.99%
BMY:
28.92%
RPRX:
-49.68%
BMY:
-70.62%
RPRX:
-35.07%
BMY:
-18.72%
Fundamentals
RPRX:
$18.61B
BMY:
$119.95B
RPRX:
$2.54
BMY:
-$3.57
RPRX:
6.86
BMY:
2.07
RPRX:
$1.67B
BMY:
$35.96B
RPRX:
$1.08B
BMY:
$24.67B
RPRX:
$1.47B
BMY:
$605.00M
Returns By Period
In the year-to-date period, RPRX achieves a 22.81% return, which is significantly higher than BMY's 7.16% return.
RPRX
22.81%
21.25%
15.93%
14.96%
N/A
N/A
BMY
7.16%
5.97%
28.79%
29.23%
1.83%
3.27%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
RPRX vs. BMY — Risk-Adjusted Performance Rank
RPRX
BMY
RPRX vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
RPRX vs. BMY - Dividend Comparison
RPRX's dividend yield for the trailing twelve months is around 2.68%, less than BMY's 4.04% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPRX Royalty Pharma plc | 2.68% | 3.29% | 2.85% | 1.92% | 1.71% | 0.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.04% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
RPRX vs. BMY - Drawdown Comparison
The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for RPRX and BMY. For additional features, visit the drawdowns tool.
Volatility
RPRX vs. BMY - Volatility Comparison
Royalty Pharma plc (RPRX) has a higher volatility of 12.41% compared to Bristol-Myers Squibb Company (BMY) at 6.02%. This indicates that RPRX's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
RPRX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Royalty Pharma plc and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities